Synthesis and biological evaluation of novel synthetic chalcone derivatives as anti-tumor agents targeting Cat L and Cat K.

[1]  A. Corrêa,et al.  Asymmetric synthesis and evaluation of epoxy-α-acyloxycarboxamides as selective inhibitors of cathepsin L. , 2017, Bioorganic & medicinal chemistry.

[2]  M. Siddiqi,et al.  Insights from molecular modeling into the selective inhibition of cathepsin S by its inhibitor , 2017, Journal of Molecular Modeling.

[3]  Zhuo-rong Li,et al.  Design, synthesis and biological evaluation of novel benzimidazole-2-substituted phenyl or pyridine propyl ketene derivatives as antitumour agents. , 2016, European journal of medicinal chemistry.

[4]  G. Maelandsmo,et al.  Nuclear cathepsin L activity is required for cell cycle progression of colorectal carcinoma cells. , 2016, Biochimie.

[5]  S. Stecko,et al.  The Synthesis of α,α-Disubstituted α-Amino Acids via Ichikawa Rearrangement. , 2016, The Journal of organic chemistry.

[6]  Ashleigh L. Barnes,et al.  Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L. , 2015, Bioorganic & medicinal chemistry.

[7]  N. Raghav,et al.  Inhibitory potential of some chalcones on cathepsins B, H and L , 2015 .

[8]  R. Kaur,et al.  Chalcones, semicarbazones and pyrazolines as inhibitors of cathepsins B, H and L , 2015, International Journal of Biological Macromolecules.

[9]  Mamta F. Singh,et al.  SAR studies of differently functionalized chalcones based hydrazones and their cyclized derivatives as inhibitors of mammalian cathepsin B and cathepsin H. , 2014, Bioorganic & medicinal chemistry.

[10]  Mamta F. Singh,et al.  Design, synthesis and docking studies of bischalcones based quinazoline-2(1H)-ones and quinazoline-2(1H)-thiones derivatives as novel inhibitors of cathepsin B and cathepsin H. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[11]  S. D. Ramalho,et al.  Synthetic Chalcone Derivatives as Inhibitors of Cathepsins K and B, and Their Cytotoxic Evaluation , 2013, Chemistry & biodiversity.

[12]  R. Pandey,et al.  Prognostic Significance of Extracellular Matrix Degrading Enzymes—Cathepsin L and Matrix Metalloproteases-2 [MMP-2] in Human Pancreatic Cancer , 2013, Cancer investigation.

[13]  Y. Na,et al.  Chalcones, inhibitors for topoisomerase I and cathepsin B and L, as potential anti-cancer agents. , 2013, Bioorganic & medicinal chemistry letters.

[14]  I. Podgorski,et al.  Macrophage cathepsin K promotes prostate tumor progression in bone , 2013, Oncogene.

[15]  Richard J. Marhöfer,et al.  Docking-based virtual screening of covalently binding ligands: an orthogonal lead discovery approach. , 2013, Journal of medicinal chemistry.

[16]  H. Okabe,et al.  Cathepsin K expression in basal cell carcinoma , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[17]  A. Nikkels,et al.  Melanotan‐associated transverse melanonychia , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[18]  N. Sahu,et al.  Exploring pharmacological significance of chalcone scaffold: a review. , 2012, Current medicinal chemistry.

[19]  J. Porco,et al.  Synthetic cyclohexenyl chalcone natural products possess cytotoxic activities against prostate cancer cells and inhibit cysteine cathepsins in vitro. , 2011, Biochemical and biophysical research communications.

[20]  K. Okumura,et al.  Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications. , 2011, Hypertension.

[21]  Yun Zheng,et al.  Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients. , 2011, Oncology letters.

[22]  A. Jensen,et al.  The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. , 2010, Clinical breast cancer.

[23]  K. R. Reddy,et al.  Synthesis and Antimicrobial Activity of Some Novel 4-(1H-Benz[d]imidazol-2yl)-1,3-thiazol-2-amines , 2010 .

[24]  V. Turk,et al.  Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis , 2010, Biological chemistry.

[25]  T. M. Rünger,et al.  Cathepsin K in melanoma invasion. , 2008, The Journal of investigative dermatology.

[26]  M. Bogyo,et al.  Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model , 2008, Biological chemistry.

[27]  J. Falgueyret,et al.  The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. , 2008, Bioorganic & medicinal chemistry letters.

[28]  O. Vasiljeva,et al.  Dual contrasting roles of cysteine cathepsins in cancer progression: apoptosis versus tumour invasion. , 2008, Biochimie.

[29]  B. Fuchs,et al.  Cathepsins and osteosarcoma: Expression analysis identifies cathepsin K as an indicator of metastasis , 2008, Molecular carcinogenesis.

[30]  A. Blejec,et al.  The expression of lysosomal proteinases and their inhibitors in breast cancer: Possible relationship to prognosis of the disease , 2008, Pathology & Oncology Research.

[31]  V. Castronovo,et al.  A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. , 2007, Cancer research.

[32]  J. Joyce,et al.  Cysteine Cathepsins and the Cutting Edge of Cancer Invasion , 2007, Cell cycle.

[33]  Bonnie F. Sloane,et al.  Cysteine cathepsins: multifunctional enzymes in cancer , 2006, Nature Reviews Cancer.

[34]  D. Brömme,et al.  The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. , 2005, Advanced drug delivery reviews.

[35]  B. Imperiali,et al.  Photophysics and biological applications of the environment-sensitive fluorophore 6-N,N-dimethylamino-2,3-naphthalimide. , 2005, Journal of the American Chemical Society.

[36]  Bonnie F. Sloane,et al.  Cysteine cathepsins in human cancer , 2004, Biological chemistry.

[37]  D. Hanahan,et al.  Multiple Roles for Cysteine Cathepsins in Cancer , 2004, Cell cycle.

[38]  P. Hogendoorn,et al.  Cathepsin K is the principal protease in giant cell tumor of bone. , 2004, The American journal of pathology.

[39]  G. Rassner,et al.  Activity, expression, and transcription rate of the cathepsins B, D, H, and L in cutaneous malignant melanoma , 2001, Cancer.

[40]  K. Tomoo,et al.  Substrate specificity of bovine cathepsin B and its inhibition by CA074, based on crystal structure refinement of the complex. , 2000, Journal of biochemistry.

[41]  J. Kos,et al.  Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review). , 1998, Oncology reports.

[42]  J. Sloane,et al.  The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. , 1997, Cancer research.

[43]  H. Kirschke,et al.  The specificity of bovine spleen cathepsin S. A comparison with rat liver cathepsins L and B. , 1989, The Biochemical journal.